在T2DM患者中,西塔利普丁对Micro150-5p的作用与左心室透静功能障碍
Aswer J Abdulkadhium1, Bassim I Mohammad1
1DEPARTMENT OF PHARMACOLOGY AND THERAPEUTICS, COLLEGE OF MEDICINE, UNIVERSITY OF AL-QADISIYAH, AL-QADISIYAH, IRAQ.
Wiadomosci lekarskie (Warsaw, Poland : 1960)
|June 17, 2025
概括
在心脏功能障碍的2型糖尿病患者中,西塔格利普丁治疗显著降低了miR-150-5p的调节. 这种miR-150-5p的减少通过减少心脏细胞死亡来增强左心室功能.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 2型糖尿病 (T2DM) 与心血管并发症的风险增加有关,包括左心室扩张性功能障碍.
- 微RNAs (miRNAs) 在调节基因表达方面发挥着至关重要的作用,并且已与糖尿病心肌病变的发病有关.
- 在心血管疾病中,miR-150-5p已成为潜在的生物标志物和治疗点.
研究的目的:
- 调查西塔格利普丁对T2DM患者左心室静脉功能障碍的影响.
- 探索西塔利普丁对miR-150-5p和炎症过程的表观遗传调节的影响.
- 确定miR-150-5p表达与糖尿病患者心脏功能之间的关系.
主要方法:
- 进行了一项横截面,描述性,观察性研究,涉及60名被诊断为左心室扩张性衰竭和T2DM的患者.
- 隔离了总RNA,并使用RT-qPCR量化了miR-150-5p的表达.
- 进行跨胸腔心声扫描以评估左心室功能参数 (LVED,LVES,LVEF).
主要成果:
- 与甲福明治疗相比,西塔格利普丁治疗导致miR-150-5p的显著下调 (P<0.0001).
- 在糖尿病患者的心脏组织中观察到miR-150-5p表达的显著减少.
- 较低的miR-150-5p水平与左心室功能改善相关.
结论:
- 在糖尿病患者的心脏组织中,miR-150-5p的表达显著减少.
- 降低miR-150-5p水平与左心室功能增强有关,可能通过减轻心肌细胞中编程细胞死亡.
- 抑制miR-150-5p可能是治疗糖尿病心脏功能障碍的新疗法.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
01:24Glucagon-like Receptor Agonists
438
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
438
01:22Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
01:22Heart Failure Drugs: β-Blockers
446
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
446